Peter C. Lucas

Also affiliated with Mayo Clinic in Arizona

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 49 papers. Top paper: “Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy”.

Omitting Regional Nodal Irradiation after Response to Neoadjuvant Chemotherapy

New England Journal of Medicine(2025)10.1056/nejmoa2414859

N/A

1.2DataRank · unranked

93 citations

Hanna Bandos, Julia White, Thomas B. Julian, Atif J. Khan, Simona F. Shaitelman +23 more

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.502

N/A

0.832DataRank · unranked

16 citations

Hanna Bandos, Peter C. Lucas, L. J. van ‘t Veer, Jia-Perng Jennifer Wei, Charles E. Geyer +15 more

Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.7

N/A

0.561DataRank · unranked

41 citations

Greg Yothers, Osama E. Rahma, Theodore S. Hong, Marcia M. Russell, Y. Nancy You +14 more

MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer

Molecular Cancer Research(2021)10.1158/1541-7786.mcr-21-0208

N/A

0.406DataRank · unranked

14 citations

Prasanna Ekambaram, Neil Carleton, Dong Hu, Linda R. Klei, Zongyou Cai +11 more

Critical protein-protein interactions within the CARMA1-BCL10-MALT1 complex: Take-home points for the cell biologist

Cellular Immunology(2020)10.1016/j.cellimm.2020.104158

N/A

0.396DataRank · unranked

13 citations

Lisa M. Maurer, Heejae Kang, Peter C. Lucas, Linda M. McAllister‐Lucas, Jing Cheng

NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps212

N/A

0.312DataRank · unranked

7 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +8 more

A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study (NRG-GI004/SWOG-S1610).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps260

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps158

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps232

N/A

0.241DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3643

N/A

0.208DataRank · unranked

3 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +9 more

Immune infiltration correlates with transcriptomic subtypes in primary estrogen receptor positive invasive lobular breast cancer

npj Precision Oncology(2024)10.1038/s41698-024-00746-z

N/A

0.208DataRank · unranked

3 citations

Sayali Onkar, Jian Zou, Yujia Li, Haley Arbore, Sai Maley +9 more

WCRC-25: A novel luminal Invasive Lobular Carcinoma cell line model

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.09.15.558023

N/A

0.165DataRank · unranked

2 citations

Emily A. Bossart, Ahmed Basudan, Nilgun Tasdemir, Osama Shiraz Shah, Kai Ding +16 more

Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3634

N/A

0.104DataRank · unranked

1 citations

Yu Guan, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Ibrahim Halil Sahin +10 more

mDia2 is an important mediator of MRTF-A-dependent regulation of breast cancer cell migration

Molecular Biology of the Cell(2024)10.1091/mbc.e24-01-0008

N/A

0.104DataRank · unranked

1 citations

Virginia Yu, Jacob Antonello, Fangyuan Chen, David Gau, Pooja A. Chawla +6 more

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Annals of Oncology(2022)10.1016/j.annonc.2022.09.159

N/A

0DataRank · unranked

450 citations

Judy E. Garber, Richard D. Gelber, Greg Yothers, Manuel Taboada, L. Ross +93 more

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes

Cancer Discovery(2022)10.1158/2159-8290.cd-22-0475

N/A

0DataRank · unranked

206 citations

Neil Carleton, Peter C. Lucas, Tullia C. Bruno, Adrian V. Lee, Dario A.A. Vignali +2 more

Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

Cancer Research(2022)10.1158/0008-5472.can-21-2576

N/A

0DataRank · unranked

86 citations

Yang Wu, Megan E. Yates, Nilgun Tasdemir, Amir Bahreini, Jian Chen +34 more

Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine

Annals of Oncology(2022)10.1016/j.annonc.2022.06.005

N/A

0DataRank · unranked

32 citations

F. Chen, Nolan Priedigkeit, D.D. Brown, Kurt R. Weiss, Rebecca Watters +9 more

BRCA1-Associated RING Domain-1 (BARD1) Loss and GBP1 Expression Enhance Sensitivity to DNA Damage in Ewing Sarcoma

Cancer Research Communications(2022)10.1158/2767-9764.crc-21-0047

N/A

0DataRank · unranked

16 citations

Jessica D. Daley, Elina Mukherjee, Rosemarie E. Venier, Claire M. Julian, Nathanael G. Bailey +11 more

Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps3647

N/A

0DataRank · unranked

4 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.tps233

N/A

0DataRank · unranked

3 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

Testing of a machine learning (ML) model for ability to predict oxaliplatin and bevacizumab (bev) benefit in NRG Oncology/NSABP C-07 and C-08.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3607

N/A

0DataRank · unranked

1 citations

Lujia Chen, Ying Wang, Chunhui Cai, Rim S. Kim, Corey Lipchik +12 more

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.4_suppl.140

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Rim S. Kim, Patrick G. Gavin, Debora Fumagalli +13 more

Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment

Nature Cancer(2023)10.1038/s43018-023-00527-w

N/A

0DataRank · unranked

76 citations

Jian Cui, Jian Zou, Carly Cardello, Anthony R. Cillo, Mostofa Rafid Uddin +12 more

Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007567

N/A

0DataRank · unranked

17 citations

Sarah Newman, Aofei Li, Marion Joy, Maureen A. Lyons, Mary P Pham +11 more

Vascular endothelial profilin-1 drives a protumorigenic tumor microenvironment and tumor progression in renal cancer

Journal of Biological Chemistry(2023)10.1016/j.jbc.2023.105044

N/A

0DataRank · unranked

16 citations

Andrew Daoud, Abigail Allen, Marion Joy, April Sagan, Sanghoon Lee +6 more

NRG-GI004/SWOG-S1610: Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps258

N/A

0DataRank · unranked

1 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +11 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps259

N/A

0DataRank · unranked

1 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +8 more

NRG GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps260

N/A

0DataRank · unranked

0 citations

Yan Lin, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, İbrahim Halil Şahin +10 more

Data from Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis

(2023)10.1158/0008-5472.c.6513817.v1

N/A

0DataRank · unranked

0 citations

Yang‐Chang Wu, Megan E. Yates, Nilgun Tasdemir, Amir Bahreini, Jian Chen +34 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps3625

N/A

0DataRank · unranked

0 citations

Greg Yothers, Scott Kopetz, Shannon L. Puhalla, Peter C. Lucas, Atif Iqbal +8 more

iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics data

Research Square(2023)10.21203/rs.3.rs-3649238/v1

N/A

0DataRank · unranked

0 citations

Min Sun, Yiheng Hu, Yue Wang, Md. Nazrul Islam, David Goerlitz +6 more

MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.09.26.614808

N/A

0DataRank · unranked

5 citations

Saigopalakrishna S. Yerneni, Lisa M. Maurer, Hannah E. Crentsil, Gabriela Nogueira Debom, Linda R. Klei +15 more

iGenSig-Rx: an integral genomic signature based white-box tool for modeling cancer therapeutic responses using multi-omics data

BMC Bioinformatics(2024)10.1186/s12859-024-05835-1

N/A

0DataRank · unranked

0 citations

Min Sun, Yiheng Hu, Yue Wang, Md. Nurul Islam, David Goerlitz +6 more

Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast Cancer

Research Square(2024)10.21203/rs.3.rs-4579052/v1

N/A

0DataRank · unranked

0 citations

Sayali Onkar, Jian Zou, Yujia Li, Haley Arbore, Sai Maley +9 more

Spatial molecular profiling of mixed invasive ductal and lobular breast cancers reveals heterogeneity in intrinsic molecular subtypes, oncogenic signatures, and mutations

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2322068121

N/A

0DataRank · unranked

16 citations

Azadeh Nasrazadani, Julia Foldi, Jennifer M. Atkinson, Celina G. Kleer, Priscilla F. McAuliffe +14 more

NRG-GI005 (COBRA): Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.4_suppl.tps261

N/A

0DataRank · unranked

17 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.tps4121

N/A

0DataRank · unranked

4 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

PARP inhibition in Ewing sarcoma: impact of germline DNA damage repair defects and activation of immunoregulatory pathways

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.18.304238

N/A

0DataRank · unranked

1 citations

Rosemarie E. Venier, Elina Mukherjee, Claire M. Julian, Jessica D. Daley, Nathanael G. Bailey +10 more

Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences

Breast Cancer Research(2021)10.1186/s13058-020-01379-3

N/A

0DataRank · unranked

31 citations

Kai Ding, William Horne, Jay K. Kolls, Tian Du, Peter C. Lucas +7 more

Canonical and Non-Canonical Roles of GRK2 in Lymphocytes

Cells(2021)10.3390/cells10020307

N/A

0DataRank · unranked

14 citations

Peter C. Lucas, Linda M. McAllister‐Lucas, Jing Cheng

A Novel Mouse Model for SNP in Steroid Receptor Co-Activator-1 Reveals Role in Bone Density and Breast Cancer Metastasis

Endocrinology(2021)10.1210/endocr/bqab094

N/A

0DataRank · unranked

9 citations

Konstantinos Verdelis, Peter C. Lucas, Shiming Jiang, Yuqing Chen, Feiqi Lu +16 more

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—Pembrolizumab experimental arm (EA) primary results.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.8

N/A

0DataRank · unranked

32 citations

Greg Yothers, Theodore S. Hong, Marcia M. Russell, Y. Nancy You, William Parker +10 more

Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.501

N/A

0DataRank · unranked

22 citations

Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas +14 more

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3618

N/A

0DataRank · unranked

7 citations

Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie +10 more

Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer:NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.tps148

N/A

0DataRank · unranked

5 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Hotspot ESR1 mutations are multimodal and contextual drivers of breast cancer metastasis

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.02.10.430701

N/A

0DataRank · unranked

5 citations

Yang Wu, Megan E. Yates, Nilgun Tasdemir, Amir Bahreini, Jian Chen +31 more

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.tps3622

N/A

0DataRank · unranked

2 citations

Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal +7 more

Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3516

N/A

0DataRank · unranked

0 citations

Marion Joy, Ying Wang, Nan Song, Rim S. Kim, Greg Yothers +12 more